SecBot SecBot
8-K ·Filed Sep 10, 2026

ONCY

ONCOLYTICS BIOTECH INC
NEUTRAL
Impact 4/10
Horizonmonths Processed2mo ago SEC0001129928-26-000055
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

This is an early preclinical data release with no immediate stock catalyst. Monitor for future clinical trial initiation or partnership announcements involving the RAS inhibitor combination.

DirectionNeutral
Confidencemedium
Horizonmonths

pelareorep

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2/3
Time to market
At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
Next catalyst
None dated

What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$0.7720
T+0 close · Sep 10, 2026 · via day close
Latest settled
−29.48%
T+20 · $0.5444 · next T+60 in 17d
Vs SPY
−31.61%
α at T+20
Latest observation
−48.58%
T+45 · FF3 residual α
  1. T+0 · Sep 10 $0.7720entry
  2. T+1 · 2mo ago −3.43%α −4.29% · $0.7455
  3. T+5 · 2mo ago −0.26%α +0.24% · $0.7700
  4. T+20 · 6w ago −29.48%α −31.61% · $0.5444
  5. T+47 · todayOpen
  6. T+60 · in 17d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech announced positive preclinical results combining its lead candidate pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. The study showed pelareorep activity was maintained in the presence of RAS inhibition without antagonism, supporting further evaluation of the combination to potentially deepen responses and delay resistance. This is an early-stage, non-clinical data readout with no financial terms or near-term catalyst disclosed, making it a modest positive signal for the pipeline but not a material event for the stock.

Key Facts

  • Preclinical study evaluated pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
  • Pelareorep activity was maintained in the presence of RAS inhibition without evidence of antagonism.
  • Greatest tumor reductions were observed in the RAS inhibitor and combination groups during initial every-other-day dosing.
  • Incremental activity from pelareorep became less evident after transitioning to weekly dosing.
  • Oncolytics plans to expand preclinical evaluation across additional dosing schedules and RAS-driven tumor models.
  • Pelareorep has received Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer.

Financial Impact

No financial figures disclosed; preclinical study with no revenue or cost impact reported.

Risk Factors

  • Preclinical results may not be predictive of clinical outcomes.
  • No timeline provided for advancing to clinical trials with the RAS inhibitor combination.
  • The company is a clinical-stage biotech with no approved products, subject to capital market and regulatory risks.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001129928-26-000055
Document: oncolyticsrascrcpreclinica.htm0001129928-26-000055
Document: 0001129928-26-000055-index-headers.html0001129928-26-000055
Document: 0001129928-26-000055-index.html0001129928-26-000055
Document: 0001129928-26-000055.txt0001129928-26-000055

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 10, 2026